Krsnaa Diagnostics Q3 FY26 – ₹1,812mn Revenue, ₹168mn PAT, Receivables Drama & PPP Dependency Exposed
1. At a Glance – The “Government ka Paisa Kab Aayega?” Story
Krsnaa Diagnostics is currently sitting at a market cap of ~₹1,861 Cr with a stock price of ₹574 — but the real drama isn’t on the stock chart, it’s in their receivables diary. The stock has fallen ~21.6% in 3 months and ~26% in 1 year, which basically means investors are treating it like that one friend who always says “kal de dunga” but never pays.
Despite operating margins of ~30% and a P/E of ~23 (cheaper than peers), the company is stuck in a strange situation: solid business, weak cash conversion. Quarterly sales are ₹159 Cr with PAT at ₹16.5 Cr, but profits dropped ~23.7% QoQ — not because business died, but because the company literally paused operations to recover dues. Yes, you read that right.
Add to this:
Debt: ₹284 Cr
Debtor days: 152 days (basically half a year waiting for money)
ROE: 9.29% (meh)
EV/EBITDA: 8.9 (tempting but suspiciously cheap)
So here’s the big question: 👉 Is this a hidden gem suffering temporary pain… or a PPP-dependent cash flow nightmare?
2. Introduction – Welcome to the World of “Government Se Paisa Aayega”
Imagine running a business where your biggest customer is the government.
Now imagine that customer pays you… whenever they feel like it.
Welcome to Krsnaa Diagnostics.
This company isn’t your typical Dr Lal Pathlabs or Metropolis. Those guys operate like normal businesses — collect money from patients, run tests, generate cash.
Krsnaa? It decided to play “public healthcare partner” — meaning it builds diagnostic infrastructure inside government hospitals and then waits patiently for payments.
And patience… is not free.
The company earns ~75% of its revenue from PPP (Public-Private Partnership) contracts. These contracts sound great on paper:
Long tenure (3–12 years)
Guaranteed patient footfall
Annual price escalation
But reality check: 👉 Governments don’t exactly follow Amazon Prime delivery timelines for payments.
So while revenue looks stable, cash flow becomes a rollercoaster.
And in Q3 FY26, management basically said:
“Enough is enough. Pay first, test later.”
They paused operations in some locations to force collections.
That’s not business-as-usual. That’s financial warfare.
Now ask yourself: 👉 When a company has to stop working just to get paid… is that power or desperation?
3. Business Model – WTF Do They Even Do?
Let’s simplify.
Krsnaa Diagnostics runs three main businesses:
1. Radiology (Big Machines, Big Money)
CT scans, MRIs
Requires heavy capex
High margins
57% of revenue
2. Pathology (Volume Game)
Blood tests, lab diagnostics
Lower margins
43% of revenue
3. Teleradiology (Remote Reading)
Doctors reading scans remotely
Scalable, asset-light
Now here’s the twist.
Most diagnostic companies are pathology-first (low capex, high margins).
Krsnaa is the opposite.
👉 It is radiology-first, which requires 2.5x higher upfront investment than traditional players.
Why do this?
Because:
Government hospitals don’t have expensive machines
Krsnaa installs them
Gets long-term contracts
Locks in patient volumes
Sounds genius, right?
But here’s the catch:
👉 High capex + slow payments = working capital nightmare
Also, their pricing is 50–70% cheaper than market rates to win tenders.
So margins depend heavily on:
Scale
Efficiency
And government actually paying
Now think: 👉 Is this a moat… or a trap disguised as scale?
4. Financials Overview – Numbers Don’t Lie, But They Do Complain
